Exposing cystic fibrosis (CF) patients to high levels of oxygen through hyperbaric oxygen treatment may make Pseudomonas aeruginosa bacterial aggregates more sensitive to antibiotics like tobramycin and easier to eradicate from the lungs, a study in patient-derived bacterial cultures reports. The study, “Hyperbaric oxygen treatment increases killing of aggregating Pseudomonas aeruginosa isolates from…
News
Results from a Phase 3 trial demonstrate that Symkevi (tezacaftor and ivacaftor combo), known as Symdeko in the U.S., is safe and can effectively improve lung clearance in children, from 6 to 11 years old, with cystic fibrosis (CF). With these results, Vertex Pharmaceuticals — the…
Later this month, the Cystic Fibrosis Foundation (CFF) will host ResearchCon, its first virtual event dedicated to cystic fibrosis (CF) science and research. Some 480 people have registered for the Feb. 28 online conference, with at least 300 of them likely to participate, said Shellie Byrum, director of community…
Emily’s Hope and Cisco have raised more than $1 million as part of Great Strides – a Cystic Fibrosis Foundation (CFF) fundraiser – becoming its top-performing national corporate team for the event. The Great Strides walk event is CFF’s largest national fundraiser that seeks to raise awareness about cystic…
“Five Feet Apart,” an upcoming romantic movie about two teens with cystic fibrosis (CF) who fall in love while undergoing treatment, now has a marketing partner — rue21. The film is set to open at theaters around the U.S. on March 15, a press release states. An apparel and…
Tobramycin, an antibiotic commonly used against Pseudomonas aeruginosa bacteria, reduces the bacteria’s load of virulence factors that impair the function of the CFTR (cystic fibrosis transmembrane conductance regulator) protein, a new study shows. The study, “Tobramycin reduces key virulence determinants in the proteome of Pseudomonas aeruginosa outer membrane vesicles,” was published in the journal…
Income level is the greatest single determinant of well-being in people with cystic fibrosis in the United States, said experts at a recent CF conference. Social worker Kim Reno, a manager at the Cystic Fibrosis Foundation’s Compass patient assistance program, estimates that actual healthcare determines only 20% of any…
Frazier Healthcare Partners has launched a new biopharmaceutical company called Recida Therapeutics, which will develop new therapies for serious antibiotic-resistant infections, including Pseudomonas aeruginosa, the leading cause of lung infections in cystic fibrosis (CF) patients. RC-01 is Recida’s lead therapy candidate for multidrug-resistant Gram-negative bacteria, a group of…
Enrollment for a Phase 3 clinical trial testing AeroVanc in patients with cystic fibrosis with methicillin-resistant Staphylococcus aureus (MRSA) lung infections is expected to be completed in the third quarter of this year — between July and September. AeroVanc is an inhaled formulation of the antibiotic vancomycin hydrochloride being developed…
SQI Diagnostics announced two new research agreements with research hospital University Health Network (UHN), Toronto, Canada, to simplify the assessment of lungs for transplant. By creating and licensing multiplexed protein assays and point-of-care diagnostic strategies, they intend to improve the health of donor organs so they can be transplanted safely…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.